We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Genmab Expands use of IDBS’ ActivityBase Xtended Edition in Hybridoma Discovery
News

Genmab Expands use of IDBS’ ActivityBase Xtended Edition in Hybridoma Discovery

Genmab Expands use of IDBS’ ActivityBase Xtended Edition in Hybridoma Discovery
News

Genmab Expands use of IDBS’ ActivityBase Xtended Edition in Hybridoma Discovery

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Genmab Expands use of IDBS’ ActivityBase Xtended Edition in Hybridoma Discovery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

IDBS has announced that Genmab BV (Utrecht, The Netherlands) has extended its use of ActivityBase Xtended Edition (ActivityBase XE) within its Hybridoma Discovery department.

Genmab initially purchased ActivityBase XE in 2006 to handle the design, capture, storage and retrieval of their plate-based screening data. Following the implementation, Genmab has more than doubled the number of ActivityBase XE licenses.

With multiple monoclonal antibody products currently in development or under evaluation to treat cancer, inflammatory conditions and infectious diseases, international biotechnology company Genmab sought a data management solution that had the flexibility to handle the data produced from the functional screening of human monoclonal antibody therapies.

ActivityBase XE enables scientists at Genmab to capture, validate and visualize the data from antibody screening in a contextually rich environment.

Arnout Gerritsen, Sr. Manager of Lead Identification at Genmab, commented: “The introduction of ActivityBase XE into our Hybridoma Discovery department has significantly improved the efficiency of our human antibody screening campaigns.

The flexibility inherent within the ActivityBase XE module enables us to use both Excel and non-Excel templates in our analysis.” He added: “Providing a context around the screening results has promoted a better understanding and enhanced decision making.”

Advertisement